Development and validation of a rapid and sensitive -/MS method for ondansetron quantification in human plasma and its application in comparative bioavailability study

Biomedical Chromatography

Volumn 24, Issue 11, 2010, Pages 1220-1227

  Moreira, Roberto F ^a   Salvadori, Myriam C ^b   Azevedo, Cristina P ^b   OliveiraSilva, Diogo ^c   Borges, Diego C ^d   Moreno, Ronílson A ^e   Sverdloff, Carlos E ^e   Borges, Ney C ^a,e,f  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b ChromAnalysis MCM Anlises Laboratoriais SA   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Faculdade de Medicina   (Brazil)

^e Synchrophar Assessoria e Desenvolvimento de Projetos Clinicos   (Brazil)

^f NONE   (Brazil)

Author keywords

Bioequivalence; HPLC; Mass spectrometry; Ondansetron; Pharmacokinetics

Indexed keywords

BIOCHEMISTRY; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; PLASMA (HUMAN);

BIOAVAILABILITY STUDY; BIOEQUIVALENCE; CONFIDENCE INTERVAL; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH-THROUGHPUT; HPLC; HUMAN PLASMAS; ITS APPLICATIONS; ONDANSETRA; TRIPLE QUADRUPOLE;

MASS SPECTROMETRY;

ONDANSETRON; TERT BUTYL METHYL ETHER;

ACCURACY; ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; BLOOD SAMPLING; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QUADRUPOLE MASS SPECTROMETRY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; VALIDATION STUDY;

EID: 77958463983     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1431     Document Type: Article

References (26)

1. Armando YP, Schramm SG, Silva Mde F, Kano EK, Koono EE, Porta V, Serra CH. Bioequivalence assay between orally disintegrating and conventional tablet formulations in healthy volunteers. International Journal of Pharmaceutics 2009; 366: 149-153.
2. Bauer S, Stormer E, Kaiser R, Tremblay PB, Brockmoller J and Roots I. Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection. Biomedical Chromatogrhaphy 2002; 16: 187-190.
3. Butcher ME. Global experience with ondansetron and future potential. Oncology 1993; 50: 191-197.
4. Chandrasekar D, Ramakrishna S and Diwan PV. A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversedphase highpressure liquid chromatography. Arzneimittelforschung 2004; 54: 655-659.
5. Colthup PV and Palmer JL. The determination in plasma and pharmacokinetics of ondansetron. European Journal of Cancer & Clinical Oncology 1989; 25(suppl. 1): S71-74.
6. Colthup PV, Felgate CC, Palmer JL and Scully NL. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. Journal of Pharmaceutical Sciences 1991; 80: 868-871.
7. Currow DC, Coughlan M, Fardell B and Cooney NJ. Use of ondansetron in palliative medicine. The Journal of Pain and Symptom Management 1997; 13: 302-307.
8. Depot M, Leroux S and Caille G. Highresolution liquid chromatographic method using ultraviolet detection for determination of ondansetron in human plasma. Journal of Chromatography B 1997; 693: 399-406.
9. Dixon CM, Colthup PV, SerabjitSingh CJ, Kerr BM, Boehlert CC, Park GR and Tarbit MH. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metabolism and Disposition 1995; 23: 1225-1230.
10. Dotsikas Y, Kousoulos C, Tsatsou G and Loukas YL. Development and validation of a rapid 96well format based liquid-liquid extraction and liquid chromatography-tandem mass spectrometry analysis method for ondansetron in human plasma. Journal of Chromatography B 2006; 836: 79-82.
11. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W and Friedman C. Singledose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatinbased chemotherapy. Journal of clinical oncology 1998; 16: 1568-1573.
12. Gregory RE and Ettinger DS. 5HT3 receptor antagonists for the prevention of chemotherapyinduced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-189.
13. Hesketh PJ. Comparative review of 5HT3 receptor antagonists in the treatment of acute chemotherapyinduced nausea and vomiting. Cancer investigation 2000; 18: 163-173.
14. Hsieh Y, Chintala M, Mei H, Agans J, Brisson JM, Ng K and Korfmacher WA. Quantitative screening and matrix effect studies of drug discovery compounds in monkey plasma using fastgradient liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2001; 15: 2481-2487.
15. Kelly JW, He L and Stewart JT. Highperformance liquid chromatographic separation of ondansetron enantiomers in serum using a cellulosederivatized stationary phase and solidphase extraction. Journal of Chromatography 1993; 622: 291-295.
16. Liu J and Stewart JT. Highperformance liquid chromatographic analysis of ondansetron enantiomers in human serum using a reversedphase cellulosebased chiral stationary phase and solidphase extraction. Journal of Chromatography B 1997; 694: 179-184.
17. Liu K, Dai X, Zhong D and Chen X. Quantitative determination of ondansetron in human plasma by enantioselective liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2008; 864: 129-136.
18. Loewen PS, Marra CA and Zed PJ. 5HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Canadian Journal of Anaesthesia 2000; 47: 1008-1018.
19. Markham A and Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapyinduced and postoperative nausea and vomiting. Drugs 1993; 45: 931-952.
20. Muller C, Schafer P, Stortzel M, Vogt S and Weinmann W. Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. Journal of Chromatography B: Analytical Technology in Biomedicine and Life Sciences 2002; 773: 47-52.
21. Oge A, Alkis N, Oge O and Kartum A. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin. Journal of Chemotherapy 2000; 12: 105-108.
22. Pritchard JF. Ondansetron metabolism and pharmacokinetics. Seminars in Oncology 1992; 19: 9-15.
23. Roila F, Hesketh PJ and Herrstedt J. Prevention of chemotherapy and radiotherapyinduced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Annals of Oncology 2006; 17: 20-28.
24. Siluveru M, Stewart JT. Enantioselective determination of S(+) and R(-)ondansetron in human serum using derivatized cyclodextrinmodified capillary electrophoresis and solidphase extraction. Journal of Chromatography B 1997; 691: 217-222.
25. Wring SA, Rooney RM, Goddard CP, Waterhouse I and Jenner WN. A sensitive radioimmunoassay, combined with solidphase extraction, for the subnanogram per ml determination of ondansetron in human plasma. Journal of Pharmaceutical and Biomedical Analysis 1994; 12: 361-371.
26. Xu X, Bartlett MG and Stewart JT. Determination of ondansetron and its hydroxy metabolites in human serum using solidphase extraction and liquid chromatography/positive ion electrospray tandem mass spectrometry. Journal of Mass Spectrometry 2000; 35: 1329-1334.